Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

NCT03987867 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
First-line Treatment

Interventions

BIOLOGICAL: CIK cell
BIOLOGICAL: Sintilimab Injection
DRUG: Pemetrexed
DRUG: Liposome paclitaxel
DRUG: Carboplatin

Sponsor

Tianjin Medical University Cancer Institute and Hospital